DaVita Beats Expectations Then Loses 16% of Its Value — Is the Dialysis Business Running Out of Room to Grow?
Shares of DaVita cratered 16% to $191.50 on August 7, erasing roughly $2.9 billion in market value, even as the broader healthcare sector traded higher. The catalyst: a Q2 earnings report that checked every box on the income statement but offered investors nothing to dream about.
The Numbers Were Good, But the Outlook Wasn't Good Enough. DaVita reported adjusted earnings of $4.02 per share, beating the consensus estimate of $3.92 by about $0.10.
Revenue came in at $3.55 billion, up 5.2% year over year, topping the $3.50 billion analysts expected. Yet instead of raising its full-year targets, management reiterated an EPS guidance midpoint of $14.65, which sits below the $14.88 consensus Wall Street had been using.
DaVita had raised guidance after Q1, so investors had priced in further upside that never came.
Patient Volumes Are Barely Moving, and That's the Real Problem. Treatment volumes were effectively flat year over year , and over the past two years, DaVita's total treatments have been stagnant.
Analysts on the earnings call noted that the two largest dialysis providers combined appear to show negative same-store treatment growth — a troubling signal for an industry where revenue depends on how many patients walk through the door three times a week. Sell-side analysts now expect revenue growth of just 2.1% over the next 12 months, a deceleration that suggests demand challenges ahead.
Revenue Per Treatment Is Shrinking, Not Growing. Revenue per treatment fell by about $2 sequentially from Q1 , pressured by a lower mix of commercially insured patients after ACA subsidy expirations and reduced phosphate binder revenue.
Management flagged a $40 million commercial-mix headwind in 2026 and $70 million in 2027 — a drag that compounds the flat-volume problem and squeezes the amount DaVita earns on every dialysis session.
Even DaVita's Biggest Backer Is Trimming. Insiders have traded DVA stock nine times in the past six months — all sales, zero purchases.
Berkshire Hathaway sold 1.22 million shares worth approximately $182.8 million in May alone , continuing a pattern of steady exits. With the stock now trading at roughly 13× its guided midpoint EPS, the valuation looks optically cheap — but only if you believe volumes can reaccelerate. Until DaVita proves that, the market is pricing in a company that is efficiently managing decline, not growth.